Journal of Clinical Endocrinology & Metabolism, Vol 81, 961-967, Copyright © 1996 by Endocrine Society

ARTICLES

Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone

E Siris, RS Weinstein, R Altman, JM Conte, M Favus, A Lombardi, K Lyles, H McIlwain, WA Murphy Jr, C Reda, R Rude, M Seton, R Tiegs, D Thompson, JR Tucci, AJ Yates and M Zimering
Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA.

Alendronate, an aminobisphosphonate, is much more potent than etidronate, an older bisphosphonate, in inhibiting osteoclast-mediated bone resorption, and unlike etidronate, therapeutic doses of alendronate are not associated with abnormal mineralization. In the present study, we compared the effectiveness, safety, and tolerability of 6 months of daily oral administration of alendronate (40 mg) with those of etidronate (400 mg) in 89 patients with clinically active Paget's disease. The primary efficacy end point was the percent change in serum alkaline phosphatase. Other end points included changes in urinary deoxypyridinoline excretion, pain, functional impairment scores, and radiological osteolysis. Tetracycline-labeled bone biopsies were obtained for histomorphometric analysis from a subset of 43 patients at the 6-month visit. The alendronate-treated group had significantly greater decreases in both serum alkaline phosphatase (79% vs. 44%) and urinary deoxypyridinoline (75% vs. 51%) than the etidronate-treated group (P < 0.001 in both cases). Normalization of serum alkaline phosphatase was much more frequent in alendronate- treated patients (63.4% vs. 17.0%; P < 0.001). Alendronate was well tolerated and had a safety profile similar to that of etidronate. Histomorphometry revealed decreased bone turnover and no qualitative abnormalities, including no direct negative effects on bone mineralization, with alendronate treatment. One patient receiving etidronate developed frank osteomalacia. Alendronate appears to be a highly effective treatment for Paget's disease of bone that offers an important therapeutic advance over etidronate.

This article has been cited by other articles:

				M. P. Whyte Paget's Disease of Bone N. Engl. J. Med., August 10, 2006; 355(6): 593 - 600. [Full Text] [PDF]

				I. R. Reid, P. Miller, K. Lyles, W. Fraser, J. P. Brown, Y. Saidi, P. Mesenbrink, G. Su, J. Pak, K. Zelenakas, et al. Comparison of a Single Infusion of Zoledronic Acid with Risedronate for Paget's Disease N. Engl. J. Med., September 1, 2005; 353(9): 898 - 908. [Abstract] [Full Text] [PDF]

				C. D. Morris and T. A. Einhorn Bisphosphonates in Orthopaedic Surgery J. Bone Joint Surg. Am., July 1, 2005; 87(7): 1609 - 1618. [Abstract] [Full Text] [PDF]

				A. A Licata Discovery, Clinical Development, and Therapeutic Uses of Bisphosphonates Ann. Pharmacother., April 1, 2005; 39(4): 668 - 677. [Abstract] [Full Text] [PDF]

				A. L. Langston and S. H. Ralston Management of Paget's disease of bone Rheumatology, August 1, 2004; 43(8): 955 - 959. [Abstract] [Full Text] [PDF]

				D. Y. Graham and H. M. Malaty Alendronate and Naproxen Are Synergistic for Development of Gastric Ulcers Arch Intern Med, January 8, 2001; 161(1): 107 - 110. [Abstract] [Full Text] [PDF]

				H. W. Woitge, H. Oberwittler, S. Heichel, A. Grauer, R. Ziegler, and M. J. Seibel Short- and Long-Term Effects of Ibandronate Treatment on Bone Turnover in Paget Disease of Bone Clin. Chem., May 1, 2000; 46(5): 684 - 690. [Abstract] [Full Text] [PDF]

				F. R. Singer, T. L. Clemens, R. A. Eusebio, and P. J. Bekker Risedronate, a Highly Effective Oral Agent in the Treatment of Patients with Severe Paget's Disease J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 1906 - 1910. [Abstract] [Full Text]

				K. Skorey, H. D. Ly, J. Kelly, M. Hammond, C. Ramachandran, Z. Huang, M. J. Gresser, and Q. Wang How Does Alendronate Inhibit Protein-tyrosine Phosphatases? J. Biol. Chem., September 5, 1997; 272(36): 22472 - 22480. [Abstract] [Full Text] [PDF]

				P. Bettica, M. Bevilacqua, T. Vago, M. Masino, E. Cucinotta, and G. Norbiato Short-Term Variations in Bone Remodeling Biochemical Markers: Cyclical Etidronate and Alendronate Effects Compared J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3034 - 3039. [Abstract] [Full Text] [PDF]

				P. C. de Groen, D. F. Lubbe, L. J. Hirsch, A. Daifotis, W. Stephenson, D. Freedholm, S. Pryor-Tillotson, M. J. Seleznick, H. Pinkas, and K. K. Wang Esophagitis Associated with the Use of Alendronate N. Engl. J. Med., October 3, 1996; 335(14): 1016 - 1021. [Abstract] [Full Text] [PDF]